-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46

Benzinga·11/05/2026 20:19:17
Leerink Partners analyst Michael Cherny maintains Medline (NASDAQ:MDLN) with a Outperform and raises the price target from $43 to $46.